Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

iscontinuation of IXEMPRA should be considered in patients who develop cardiac ischemia or impaired cardiac function due to reports of cardiovascular adverse reactions (e.g., myocardial ischemia, superventricular arrhythmia, and ventricular dysfunction). The frequency of cardiac adverse reactions (myocardial ischemia and ventricular dysfunction) was higher in the IXEMPRA in combination with capecitabine (1.9%) than in the capecitabine alone (0.3%) treatment group.

POTENTIAL FOR COGNITIVE IMPAIRMENT FROM EXCIPIENTS

IXEMPRA contains dehydrated alcohol USP. Consideration should be given to the possibility of central nervous system and other effects of alcohol.

ADVERSE REACTIONS

The most common adverse reactions (greater than or equal to 20%) reported by patients receiving IXEMPRA were peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoskeletal pain. The following additional events occurred in greater than or equal to 20% in combination treatment: palmar-plantar erythrodysesthesia (hand-foot) syndrome, anorexia, abdominal pain, nail disorder, and constipation. Drug-associated hematologic abnormalities (>40%) include neutropenia, leukopenia, anemia, and thrombocytopenia.

About Bristol-Myers Squibb

For more than 40 years, Bristol-Myers Squibb has been committed to building a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists in Bristol-Myers Squibb's Research & Development organization are studying ways to improve current cancer treatments and identify better, more effective medicines for the future. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

For mor
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , GAITHERSBURG, Md., Aug. 27 GenVec, ... into a purchase agreement with a single institutional investor for the sale ... shares of its common stock. The shares of common stock and ... stock and 0.50 warrants to purchase one share of common stock at ...
... Elbit Imaging Ltd.,("EMI" or the "Company") (NASDAQ: EMITF ... the Page" of Series B Notes of the Company,that the interest ... August 21, 2009 and ending on February 20, 2010 is 1.723125%. ... The Activities of Elbit Imaging Ltd. are divided ...
Cached Biology Technology:Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 2Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 3
(Date:7/25/2014)... in the International Journal of Cancer earlier ... cancer based on findings showing successful reduction in the ... population of cells in the cervix. , The ... junction cells, or SCJ cells. These cells reside in ... origins of cervical cancer. A research team co-led by ...
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... at the University of Houston, has written a ... development., "Introduction to Tissue Engineering: Applications and Challenges" ... field of artificial organ development. Metin Akay, founding ... served as a series editor on the book., ... books on the subject of growing artificial organs ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2University of Houston researcher publishes textbook on tissue engineering 2
... , During heavy rain, the lid of Nepenthes ... that seek shelter on its underside directly into the ... published today, Wednesday 13 June, in the journal ... insects as a source of nutrients, enabling them to ...
... unfathomable only a few years ago are reality today ... the acquisition of next-generation sequencing technology on the Texas ... of the service. "As we move into the ... in history," said Dr. Charles Johnson, director of the ...
... wide range of diseases and uncover fundamental processes that lead ... for biomedical science. A number of hurdles, both scientific and ... of using these special cells to treat heart disease, diabetes, ... June 13 in Nature , scientists at the Salk ...
Cached Biology News:Pitcher plant uses rain drops to capture prey 2Next-generation sequencing technology opens doors to discoveries 2'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics 2'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics 3
BOND ELUT MATRIX-C18, 25 mg ...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human Legumain Affinity Purified Polyclonal Ab...
Biology Products: